share_log

NanoVibronix Issues Letter To Stockholders

NanoVibronix Issues Letter To Stockholders

NanoVibronix 向股東發出信函
Benzinga ·  04/09 08:55

We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase value for our stockholders. We are focused on several areas that we believe will have a substantial impact on our growth and product adoption. Many of those areas of focus have begun showing positive results, as reflected in our most recent quarterly financial results. Our products continue to deliver impressive results with high patient satisfaction, with no adverse events. We are investing in sales improvement and long-term opportunities with all of our products.

我們致力於實現我們的戰略願景，即開發、改進和商業化我們獨特而有效的療法，我們相信這些療法使醫療保健提供者能夠治療有需要的患者，填補市場空白，並有可能爲我們的股東增加價值。我們專注於幾個領域，我們認爲這些領域將對我們的增長和產品採用產生重大影響。正如我們最近的季度財務業績所反映的那樣，其中許多重點領域已開始顯示出積極的業績。我們的產品繼續提供令人印象深刻的結果，患者滿意度高，沒有不良事件。我們正在投資所有產品的銷售改善和長期機會。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論